IS2819B - Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra - Google Patents

Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra

Info

Publication number
IS2819B
IS2819B IS6072A IS6072A IS2819B IS 2819 B IS2819 B IS 2819B IS 6072 A IS6072 A IS 6072A IS 6072 A IS6072 A IS 6072A IS 2819 B IS2819 B IS 2819B
Authority
IS
Iceland
Prior art keywords
adhesion molecules
formulation
activity
vascular adhesion
cram
Prior art date
Application number
IS6072A
Other languages
English (en)
Other versions
IS6072A (is
Inventor
Beat Albert Imhof
Michel Aurrand-Lions
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of IS6072A publication Critical patent/IS6072A/is
Publication of IS2819B publication Critical patent/IS2819B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS6072A 1999-03-11 2001-09-10 Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra IS2819B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (2)

Publication Number Publication Date
IS6072A IS6072A (is) 2001-09-10
IS2819B true IS2819B (is) 2012-12-15

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6072A IS2819B (is) 1999-03-11 2001-09-10 Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra

Country Status (23)

Country Link
US (3) US7393651B2 (is)
EP (2) EP1163337B1 (is)
JP (2) JP4836329B2 (is)
CN (2) CN100469878C (is)
AT (1) ATE500328T1 (is)
AU (1) AU782139B2 (is)
BR (1) BR0008915A (is)
CA (1) CA2362896C (is)
CZ (1) CZ303128B6 (is)
DE (1) DE60045681D1 (is)
EE (1) EE05497B1 (is)
ES (1) ES2361905T3 (is)
HK (1) HK1044169A1 (is)
HU (1) HU229376B1 (is)
IL (1) IL145310A0 (is)
IS (1) IS2819B (is)
MX (1) MXPA01009110A (is)
NO (1) NO333085B1 (is)
NZ (1) NZ514091A (is)
PL (1) PL207994B1 (is)
RU (1) RU2244748C2 (is)
WO (1) WO2000053749A2 (is)
ZA (1) ZA200107283B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
RU2244748C2 (ru) * 1999-03-11 2005-01-20 РМФ Диктажен С.А. Адгезивные молекулы сосудов и модуляция их функций
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
EP2068928A2 (en) 2006-09-28 2009-06-17 Merck Serono SA Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
AR063760A1 (es) 2006-11-02 2009-02-18 Genentech Inc Anticuerpos anti-factor d humanizados y usos de los mismos
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
BRPI0815094B8 (pt) * 2007-08-06 2023-04-18 Noxxon Pharma Ag Uso de uma molécula de ácido l-nucleico ligada a sdf-1
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
WO1998040483A2 (en) * 1997-03-14 1998-09-17 Human Genome Sciences, Inc. 28 human secreted proteins
WO1998042739A2 (en) * 1997-03-21 1998-10-01 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999006551A2 (en) 1997-08-01 1999-02-11 Genset 5' ESTs FOR SECRETED PROTEINS IDENTIFIED FROM BRAIN TISSUES
US20030044839A1 (en) 1997-09-17 2003-03-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
IL142794A0 (en) * 1998-12-16 2002-03-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
RU2244748C2 (ru) * 1999-03-11 2005-01-20 РМФ Диктажен С.А. Адгезивные молекулы сосудов и модуляция их функций
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
CN100469878C (zh) 2009-03-18
WO2000053749A3 (en) 2000-12-14
MXPA01009110A (es) 2002-08-20
ATE500328T1 (de) 2011-03-15
AU4105100A (en) 2000-09-28
JP2002537837A (ja) 2002-11-12
CA2362896C (en) 2012-07-31
JP4836329B2 (ja) 2011-12-14
NO20014417L (no) 2001-11-12
HK1044169A1 (en) 2002-10-11
EP2292761A1 (en) 2011-03-09
CZ20013267A3 (cs) 2002-02-13
EP1163337B1 (en) 2011-03-02
US8143056B2 (en) 2012-03-27
CN1355843A (zh) 2002-06-26
PL207994B1 (pl) 2011-02-28
CZ303128B6 (cs) 2012-04-18
NO20014417D0 (no) 2001-09-11
US20100267649A1 (en) 2010-10-21
US20050266426A1 (en) 2005-12-01
ZA200107283B (en) 2002-12-24
IL145310A0 (en) 2003-01-12
RU2244748C2 (ru) 2005-01-20
CA2362896A1 (en) 2000-09-14
EP1163337A2 (en) 2001-12-19
HUP0200606A3 (en) 2004-11-29
US7670826B2 (en) 2010-03-02
PL350417A1 (en) 2002-12-16
BR0008915A (pt) 2002-04-09
WO2000053749A2 (en) 2000-09-14
AU782139B2 (en) 2005-07-07
ES2361905T3 (es) 2011-06-24
JP2010233572A (ja) 2010-10-21
US7393651B2 (en) 2008-07-01
NZ514091A (en) 2004-01-30
HUP0200606A2 (en) 2002-06-29
CN1637019A (zh) 2005-07-13
EE200100472A (et) 2002-12-16
DE60045681D1 (de) 2011-04-14
NO333085B1 (no) 2013-02-25
US20080274970A1 (en) 2008-11-06
HU229376B1 (en) 2013-11-28
EE05497B1 (et) 2011-12-15
IS6072A (is) 2001-09-10

Similar Documents

Publication Publication Date Title
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
DE69427650T2 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE3876400T2 (de) Aminosaeure-imid-derivate, ihre verwendung und diese enthaltende medizinische zusammensetzungen.
NO873699D0 (no) Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser.
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
ES2177625T3 (es) Citoquina cc-1 humana circulante.
FI893681A (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
BR9007115A (pt) Novo trombolitico
DK0610698T3 (da) Substituerede imidazo[4,5-b]pyridiner og benzimidazoler som angiotensin II-antagonister
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
DE69836278D1 (de) Allele formen von menschlichem stat3
DE69737293D1 (de) Nukleotidsequenz, die für eine flavinmonooxygenase kodiert, das korrespondierende protein, sowie deren verwendungen in diagnostik und therapie
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
DK0423326T3 (da) Hidtil ukendt fysiologisk aktivt peptid og calcium-metabolisme-regulerende middel, der omfatter peptidet som effektiv besta
DE500713T1 (de) Derivate des 3,3,5-trimethylcyclohexylesters von 2-methylpropionsaeure, ihr herstellungsverfahren sowie diese enthaltende therapeutische kompositionen.